# Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

Source: https://onco.cc/trials/nct06801834/  
OnCo record `nct06801834` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Sacituzumab govitecan, Topotecan, Amrubicin in small-cell lung cancer, run by Gilead Sciences, now recruiting.

## Summary

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06801834 by Gilead Sciences, with 695 participants planned, started 2025-04-04 and due to reach its primary completion in 2029-10. Interventions recorded: Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only), Lurbinectedin (regions/countries where approved and available). Conditions listed: Extensive Stage Small Cell Lung Cancer (ES-SCLC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06801834
- Phase: 3
- Setting: A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Sponsor: Gilead Sciences
- Enrolled: 695

## Sources

- ClinicalTrials.gov NCT06801834: https://clinicaltrials.gov/study/NCT06801834

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Amrubicin](https://onco.cc/drugs/amrubicin/), [Lurbinectedin](https://onco.cc/drugs/lurbinectedin/), [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/), [Topotecan](https://onco.cc/drugs/topotecan/)
- companies: [Gilead Sciences (incl. Kite)](https://onco.cc/companies/gilead/)

---
JSON: https://onco.cc/api/v1/entities/nct06801834.json